Nanotransportadores inmunomoduladores en la esclerosis múltiple: doble direccionamiento de la microglía y las mitocondrias para una neuroterapia de precisión

neuroprotective effects. Even with promising preclinical findings, there are still obstacles to overcome to achieve clinical translation, scale up production, and ensure long-term safety. Early microglial modulator experiments using sophisticated delivery devices show promise. Finally, dual-targeting immunomodulatory nanocarriers present a new precision neurotherapy strategy for multiple sclerosis. Sustained improvement of clinical pathways, safety, and pharmacokinetics may revolutionize therapeutic approaches and enhance patient Copyright© Bentham Science Publishers; For any queries, please email at